Is Stealth Bio Done After Mitochondrial Myopathy Study?
Stealth Bio shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy (PMM). Specifically, the top-line results are coming from the Phase 3 MMPower-3 trial evaluating elamipretide.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Stealth BioTherapeutics Corp. (NASDAQ: MITO) shares were absolutely crushed on Friday after the firm announced results from its late-stage study in patients with primary mitochondrial myopathy. Specifically, the top-line results come from the Phase 3 MMPower-3 trial evaluating elamipretide.
Unfortunately, the study did not meet its primary endpoints assessing changes in the six-minute walk test and Primary Mitochondrial Myopathy Symptom Assessment Total Fatigue Score.
Safety results demonstrated that treatment with elamipretide was well tolerated, with most adverse events mild to moderate in severity.
Looking ahead, Stealth Bio said that it plans to review its operational resources to align them with its near-term priorities of progressing its Barth, AMD and pipeline programs. The company expects to provide further guidance next month.
CEO Reenie McCarthy commented:
We are deeply grateful to our patients and families, our investigators and their teams, and our advocacy partners for their support of this study, and share their disappointment that it did not meet the promise of our earlier trials in this indication. We remain confident in the promise of our platform and committed to our mission of improving the lives of people living with diseases involving mitochondrial dysfunction. We plan to meet with the FDA in early 2020 regarding our Barth syndrome program, where we have observed significant improvement in cardiac stroke volume during open-label extension, and continue to enroll our Phase 2b clinical trial in geographic atrophy associated with dry age-related macular degeneration, in which we observed improvement in visual function during an earlier Phase 1 study. We are also progressing our pipeline of second-generation mitochondrial therapeutics, with lead pipeline compound SBT-272 entering Phase 1.
[nativounit]
Shares of Stealth Bio were last seen down about 65% at $4.84, in a 52-week range of $4.26 to $20.99. The consensus price target is $23.17.
[recirclink id=599773]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
